EDAP TMS S.A.

What they do

EDAP develops and sells non-invasive therapeutic ultrasound devices, primarily the Focal One Robotic HIFU system for prostate tissue ablation. It also markets legacy ESWL systems and distributes third-party urology products, though these are now classified as discontinued operations. Revenue comes from capital equipment sales, consumables, and maintenance services.

Revenue drivers

• Focal One Robotic HIFU capital sales — Flagship product; 13 systems sold in Q2 2026 (up from 9 prior year), including 2 lease conversions; installed base of 184 systems (96 U.S., 88 international).
• Recurring revenue from consumables and services — Maintenance and consumables tied to installed base; contributes to stable recurring revenue stream.
• Legacy ESWL and distribution — Non-core product lines still generate revenue in select markets but are being divested; reported as discontinued operations from Q2 2026.

Recent performance

Q2 2026 (continuing operations) revenue grew 39% year-over-year to $13.2 million, with U.S. procedure volume up 47%. Gross margin improved to 55.6% from 51.1%. Operating loss widened to $8.0 million from $6.6 million, and net loss increased to $14.4 million ($0.38 per share) from $6.4 million ($0.17), driven partly by a $5.5 million EIB warrant valuation charge. Cash and equivalents were $21.5 million at June 30, 2026. Annual 2025 revenue was $70.5 million with a net loss of $29.2 million.

Strategy

Management is focusing exclusively on HIFU technology, particularly the Focal One platform, and has reclassified ESWL and distribution as discontinued operations. Plans include expanding indications into benign prostatic hyperplasia (BPH) and endometriosis, with the first commercial endometriosis program launched in Europe. The company is investing in AI-assisted treatment, FocalConnect telecollaboration, and integrating histotripsy with HIFU. A $40 million underwritten public offering was announced to fund commercial adoption and R&D.

Risks

• Financing and liquidity — Negative operating cash flow and net losses require additional capital; ability to continue depends on securing financing.
• Debt obligations — Substantial debt, including EIB warrants, creates cash flow demands and potential dilution.
• Regulatory and clinical uncertainty — Expanded indications (BPH, endometriosis) depend on clinical success and regulatory approvals; reimbursement uncertainty remains.
• Market and operational execution — Cyclical demand, competition, and reliance on strategic suppliers and distributors could impact results; tariffs and geopolitical risks also cited.

Outlook

Management reiterated 2026 guidance for continuing operations of $50-54 million in revenue, representing 34-45% growth over 2025. They expect to accelerate HIFU adoption in prostate cancer and pursue endometriosis and BPH opportunities. The company anticipates the Focal One platform will enable multi-indication growth and higher-margin revenue over time.